10 nov: Aktietilbagekøbsprogram
10 nov: Indre værdi af SmallCap Danmark A/S er opgjort til 82,7 kr. pr. ..
10-11-2017 07:30:00

Nine-month interim report (Q3) 2017

Relateret indhold
13 aug - 
Mandagens aktier: GN og Coloplast bragte C25 i europæis..
13 aug - 
ALK-Abelló/Danske: Anbefalingen bliver sænket til "sælg..
13 aug - 
Aktier/middag: Har genfundet roen, men DFDS i fortsat t..
Relateret debat
13 aug - 
Sydbank.. :https://data.sydbank.dk/api/investment/sydba..
13 aug - 
Forventer bestemt ikke et dårligt regnskab. Det bliver ..
13 aug - 
Med disse besynderlige udmeldinger der stikker i alle r..

København, 2017-11-10 07:30 CET (GLOBE NEWSWIRE) --

 

Bemærk venligst, at kvartalsrapporten kun foreligger på engelsk.  

Performance for the period (unaudited)

(Comparative figures for 2016 are shown in brackets. Revenue growth is measured in local currencies. 2016 comparative figures are affected by last year's market disruptions which boosted ALK's sales and earnings in Europe significantly. To provide a meaningful benchmark, comparisons to figures from 2015 have also been included in the report wherever relevant.)

During Q3 2017, ALK continued its investment programme to scale-up and build a pharma company in North America, defend its European leadership position and upgrade its product supply. ALK will continue to invest to deliver its long-term growth plans.    

Q3 2017 highlights:

  • Sales growth in Europe, North America and International markets showed good progress in line with expectations.

  • Total revenue increased 7% to DKK 667 million (630), with European revenue 23% higher organically than 'pre-market disruption' levels in Q3 2015.

  • Constraints in SCIT production capacity are estimated to have negatively impacted Q3 sales by DKK 50-60 million.

  • Operating profit (EBITDA) was DKK 36 million (110) following planned cost increases to support long-term growth, including the launch of the HDM SLIT-tablet in North America and to secure robustness in ALK's product supply operations.

  • 9M total revenue amounted to DKK 2,147 million (2,251) and 9M operating profit (EBITDA) was DKK 192 million (546).

Business priorities

  • Investments in the North American scale-up to support the launch of SLIT-tablets are ongoing. In August, the marketing authorisations were transferred to ALK from the FDA. In November, ALK has launched the HDM SLIT-tablet as ACARIZAX® in Canada and has started pre-launch and marketing activities ahead of the launch in the USA, where the brand name will be ODACTRA™. Market access in the USA is progressing well.

  • Investments to defend and retain market leadership in Europe continue and showed good results in Q3.

  • ACARIZAX® sales in Europe roughly doubled in Q3, while development, registration and market access activities are progressing.

  • Investments in securing a robust product supply continue. Robust inventory levels are expected to be gradually rebuilt during 2018.

  • In December 2017, ALK will be presenting an updated strategy that is designed to stimulate a new era of growth by continuing ALK's investments in its core AIT franchise while also leveraging its position and expertise to engage with more patients and to capture a larger share of the total allergy market.

2017 financial guidance

ALK's financial guidance for full-year revenue has been narrowed while guidances for operating profit (EBITDA) and free cash flow remain unchanged:

  • Full-year revenue is now projected at approximately DKK 2.9 billion (previously DKK 2.8-3.0 billion) as European markets establish a 'new normal' following last year's disruptions. 

  • Operating profit (EBITDA) is still expected to be DKK 225-250 million.

  • Free cash flow is still expected at approximately minus DKK 700 million.

Hørsholm, 10 November 2017

ALK-Abelló A/S

 

For further information, contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014 

Today, ALK is hosting a conference call for analysts and investors at 10.00 a.m. (CET) at which Management will review the financial results and the outlook. The conference call will be audio cast on http://ir.alk.net/. Participants for the audio cast are kindly requested to call in before 9.55 a.m. (CET). Danish participants should call in on tel. +45 7022 3500 and international participants should call in on tel. +44 (0) 20 7572 1187 or +1 646 722 4972. Please use the Participant Pin Code: 28359539#. The conference call will also be webcast live on our website, where the related presentation will be made available shortly before the call begins.  

Vedhæftet fil: FM_30_17UK_10112017.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
13 aug
ALK-B
Der er to banker der har nedjusteret aktien i dag. Danske Bank til Sælg og DnB til Hold.
1
13 aug
ALK-B
Ser det ud til at vi skal have et dårligt regnskab fra alk-den fakder over 5% i dag. 
1

NKT OPTAKT Q2 15/8: Priser, guidance og 2019-indikationer i fokus

14-08-2018 11:30:02
Når kabelkoncernen NKT onsdag aflægger regnskab for andet kvartal vil der være fokus på, om selskabet ændrer på forventningerne til 2018. Derudover vil opmærksomheden rette sig mod eventuelle kommentarer om udsigterne for 2019, herunder prisudviklingen og mulighederne for at få flere ordrer i bogen for at sikre en bedre udnyttelse af selskabets produktionskapacitet.Hos Jyske Bank venter aktieanaly..

Aktier/tendens: Nilfisks regnskab og flere opjusteringer i fokus

14-08-2018 08:40:16
Et regnskab fra Nilfisk og flere selskaber med opjusteringer kan præge udviklingen på den københavnske fondsbørs tirsdag morgen blandt de mindre selskaber, der ikke er med i eliteindekset, C25.Her er det så som så med nyheder - måske lige med undtagelse af Vestas, der fra morgenstunden har fået nyt fra de tyske konkurrenter Senvion og Nordex, der begge er kommet med regnskaber, op til at Vestas se..

GN/CEO: Nyt produkt har en vigtig rolle i at nå vækstforventninger -NY

13-08-2018 15:41:26
Selv om det kom som en overraskelse for markedet, at GN Group mandag offentliggjorde planerne om lanceringen af et nyt høreapparat, så har det hele tiden været planen internt i høreapparatkoncernen, at det nye premiumapparat skulle lanceres efter sommer.Den kommende lancering af produktet, der går under navnet Resound Linx Quattro, kommer derfor heller ikke sammen med en ændring af vækstforventnin..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas/Sydbank: Vingeskudte rivaler kæmper en hård kamp
2
Valuta/Danske: Erdogans budskab får liraen til at miste pusten
3
Tirsdagens aktier: Vestas i bund og Novo i top - KORR
4
KORR: Aktier/middag: Nilfisk straffes og opjusteringer belønnes
5
Aktier/tendens: Nilfisks regnskab og flere opjusteringer i fokus

Relaterede aktiekurser

ALK-Abelló B A/S 1.078,00 1,7% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
15. august 2018 01:52:28
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180814.1 - EUROWEB2 - 2018-08-15 01:52:28 - 2018-08-15 01:52:28 - 1 - Website: OKAY